Multiply Labs

Robotics has the potential to transform biotech, but building for the lab comes with a unique set of challenges. I sat down with Multiply Labs CEO Fred (Federico) Parietti for a chat about why Fred started the company, what makes biotech manufacturing so difficult to automate, and how robotics could help make advanced medicines more accessible. Fred also explains what it takes to build reliable robotic systems for highly regulated environments, the lessons Multiply Labs has learned along the way, and the impact this technology could have on the future of cell and gene therapies, antibodies, and other advanced biologics.

I'm excited to share my feature in Foxglove’s new case study on how we build the full stack for robotic manufacturing at Multiply Labs! As a robotics engineer, I often find myself asking: what did the robot do and when did it do it? At Multiply Labs, we build robotic clusters that manufacture cell and gene therapies, and a single system is not just one robot. It has precise robotic arms, humanoid robots, and proprietary subsystems working in parallel, each producing its own events and sensor data. When you debug a system like that, the hard part is rarely the fix. It is reconstructing what happened across every subsystem in the seconds around an event. Answering that question used to take two to three hours of gathering logs and stitching an event back together by hand. Now it takes seconds thanks to Foxglove. We stream every robotic event in our cluster to the cloud through a single Foxglove Agent. Instead of asking "where is the data?" I start at "what is the data telling us?" I can compare signals, replay robot behavior in 3D, and see how the subsystems interacted, all from one place. That is what lets us learn from every run and keep improving the robots that make advanced therapies. It is also the foundation for what comes next: I am now working on new features that let us train our robots on this data, so every run makes the next one better. Huge thanks to Adrian Macneil and the Foxglove team for building something our engineers rely on every day! Check out the full case study in the comments below.

It was a pleasure to sit down with Adrian Macneil and the Foxglove team to showcase how Multiply Labs is using Foxglove to help us build 𝗽𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝗔𝗜 𝗳𝗼𝗿 biomanufacturing. The next generation of biological therapies are being rapidly discovered and approved for patient use. The bottleneck is manufacturing. We believe that a fully robotic factory is the only way to manufacture biological therapies of all types at scale. One lesson keeps proving itself: 𝘀𝗰𝗮𝗹𝗶𝗻𝗴 𝗿𝗼𝗯𝗼𝘁𝘀 𝗶𝘀 𝗮 𝗱𝗮𝘁𝗮 𝗽𝗿𝗼𝗯𝗹𝗲𝗺. Instead of manually stitching together logs, our team streams every robotic event to the cloud through the Foxglove Agent and understands system behavior from one place. Check out the full case study and video in the comments below!

It's the summer of 2026, and our interns are back at it again - this time using 𝗩𝗥 𝗵𝗲𝗮𝗱𝘀𝗲𝘁𝘀 for 𝗳𝘂𝗹𝗹-𝗯𝗼𝗱𝘆 𝘁𝗲𝗹𝗲𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻 of our 𝙝𝙪𝙢𝙖𝙣𝙤𝙞𝙙 𝙧𝙤𝙗𝙤𝙩𝙨! Why does this matter? At Multiply Labs, we believe a 𝗳𝘂𝗹𝗹𝘆 𝗿𝗼𝗯𝗼𝘁𝗶𝗰 𝗳𝗮𝗰𝘁𝗼𝗿𝘆 is the only way to manufacture biological therapies of all types at scale, with:  • Lower contamination risk  • Higher reliability  • More affordable manufacturing  • Up to 100x throughput (per sq. ft) We also believe in empowering our interns to work on the cutting edge of 𝗽𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝗔𝗜. Here is a sneak peek of the initial tests: teleoperating the humanoid to push trolleys with a full-body control model - the first step toward humanoids loading and unloading the trolleys that move materials across our robotic floor. Super proud of what this team has already achieved!! Our mission is to build the world's best robots and use them to 𝗺𝗮𝗸𝗲 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝗱𝗲𝗹𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲. If you are a roboticist and you love to build robots that make a real, positive impact, do not hesitate to reach out! #robotics #physicalai #humanoid #biologics #advancedtherapies

Some innovations improve processes.   Others redefine entire industries.  Cell & Gene Therapies are opening a new frontier in personalized medicine.   The challenge now is no longer only scientific.   It is industrial.  How do we transform breakthrough therapies into scalable, reliable, and accessible manufacturing models?  This is where the partnership between Fedegari and Multiply Labs begins.   A convergence between advanced robotics, aseptic expertise and industrial vision designed to shape the future of pharmaceutical manufacturing.   This new edition of Leading with Knowledge explores how innovation becomes industrial reality - and why scalability will define the next era of advanced therapies.  Frontiers: Fedegari Conversations.   A conversation format dedicated to the ideas, technologies and strategic visions redefining the pharmaceutical industry.   In this episode, our Group General Manager Stefano Nanni and Fred (Federico) Parietti, CEO and Co-Founder of Multiply Labs, discuss the future of Cell & Gene manufacturing, automation and scalable aseptic production.  🔗 Read the latest edition of Leading with Knowledge   

Multiply Labs is automating cell therapy manufacturing with robots, reducing costs by more than 70%. Read the blog to learn more > https://nvda.ws/4wcJrEq